Predicting the Effectiveness of Insulin Pump Therapy on Glycemic Control in Clinical Practice: A Retrospective Study of Patients with Type 1 Diabetes from 10 Outpatient Diabetes Clinics in Sweden over 5 Years
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Multicenter long-term studies of predictors for the effectiveness of continuous subcutaneous insulin infusion (CSII) in clinical practice are lacking. We hypothesized that there are substantially greater reductions in hemoglobin A1c (HbA1c) in patients with poor glycemic control and that other predictors may also exist. SUBJECTS AND METHODS: We used data from 10 outpatient diabetic clinics in Sweden and studied CSII treatment over 5 years. Patients with HbA1c values available ≤ 6 months before starting CSII and at 5 years were included (n = 272, 82% of CSII patients) along with 2,437 contemporaneous controls on multiple daily insulin injections (MDI). Baseline variables evaluated were age, sex, diabetes duration, insulin dose, body mass index (BMI), HbA1c at baseline, and outpatient clinical care unit. RESULTS: At 5 years, significantly greater reductions in HbA1c by CSII compared with MDI were found for patients with higher baseline HbA1c (P = 0.032) and lower baseline BMI (P = 0.013). For baseline HbA1c levels of 7.0%, 8.0%, and 9.0% and a BMI of 25 kg/m(2), the reduction in HbA1c level by CSII was 0.08% (difference not significant), 0.16% (95% confidence interval, 0.03-0.29%), and 0.25% (95% confidence interval, 0.11-0.39%), respectively. Corresponding analyses for the change in HbA1c level from start to 1 and 2 years revealed a significant interaction of insulin pump therapy only with baseline HbA1c levels (P < 0.001 and P = 0.030, respectively). The interaction term between outpatient clinical care unit and CSII treatment was statistically significant for some care units, with some care units demonstrating a benefit from CSII and others demonstrating a detriment. CONCLUSIONS: Patients with high HbA1c levels have a greater probability of improved HbA1c after initiating pump therapy, but effects remain relatively modest even for patients with poor control. Factors predicting successful insulin pump use need further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894 · cited 1×
“35 In conclusion, this study shows that changing therapy to CSII from MDI in clinical practice may improve glycemic control in patients with impaired or poor glycemic control.”
Hoelzel, W., Weykamp, C., Jeppsson, J.-O., Miedema, K., Barr, J. R., Goodall, I., Hoshino, T., John, W. G., Kobold, U., Little, R., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.024802 · Cited by 690 · cited 1×
“Because diabetes clinics in Sweden used HbA1c methods calibrated to the highperformance liquid chromatography Mono-S method until September 2010, all HbA1c values were converted to the National Glycohemoglobin Standardization Program and International Federation for Clinical Chemistry standards.(20) Percentage units a…”
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541 · cited 1×
“31 In a previous clinical study, we found greater reductions in HbA1c level when introducing CGM in clinical practice than those observed here by CSII alone, 15 but this finding needs further examination in larger patient populations and over longer follow-up.”
Miller, K. M., Beck, R. W., Bergenstal, R. M., Goland, R. S., Haller, M. J., McGill, J. B., Rodriguez, H., Simmons, J. H., Hirsch, I. B., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1770 · Cited by 505
Cited by
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
Introduction to real-world evidence studies
Chodankar, D. (2021) · Perspectives in Clinical Research · doi:10.4103/picr.picr_62_21 · Cited by 153
Heller, S., White, D., Lee, E., Lawton, J., Pollard, D., Waugh, N., Amiel, S., Barnard, K., Beckwith, A., Brennan, A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21200 · Cited by 73
Kampmann, U., Madsen, L. R., Bjerg, L., Witte, D. R., Hasselstrøm, K., Østergård, T., Alstrup, K., Møller, M. K., Dylmer, D., & Hansen, K. W. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.042 · Cited by 19
Metadata
- Authors
- Clements, M., Matuleviciene, V., Attvall, S., Ekelund, M., Pivodic, A., Dahlqvist, S., Fahlén, M., Haraldsson, B., & Lind, M.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2015-01
- Volume
- 17
- Issue
- 1
- Pages
- 21-28
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W1269870195
- Cited by
- 27
- References
- 5
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting the Effectiveness of Insulin Pump Therapy on Glycemic Control in Clinical Practice: A Retrospective Study of Patients with Type 1 Diabetes from 10 Outpatient Diabetes Clinics in Sweden over 5 Years. https://app.cochat.ai/papers/10.1089/dia.2014.0139
- The paper
- Clements, M., Matuleviciene, V., Attvall, S., Ekelund, M., Pivodic, A., Dahlqvist, S., Fahlén, M., Haraldsson, B., & Lind, M. (2015). Predicting the Effectiveness of Insulin Pump Therapy on Glycemic Control in Clinical Practice: A Retrospective Study of Patients with Type 1 Diabetes from 10 Outpatient Diabetes Clinics in Sweden over 5 Years. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2014.0139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.